Concordance in postsurgical radioactive iodine therapy recommendations between Watson for Oncology and clinical practice in patients with differentiated thyroid carcinoma
Abstract
Background: To the authors' knowledge, the indications for radioactive iodine (RAI) therapy in patients with differentiated thyroid carcinoma (DTC) are unclear; treatment decisions are based on physician judgment. The objective of the current study was to identify the degree of concordance between postsurgical RAI therapy recommended by Watson for Oncology (WFO), a clinical decision support system for oncological therapy, and that recommended by physicians for patients with DTC. Methods: The current retrospective cohort study included 207 patients with DTC who underwent thyroidectomy between 2017 and 2018. Treatment recommendations were considered concordant if WFO rendered recommendations consistent with those of the physicians. Results: Treatment recommendations were concordant for 160 patients (77%). The concordance rate significantly differed according to the American Thyroid Association (ATA) risk category ( P < .001) and American Joint Committee on Cancer TNM stage (seventh edition; P = .004). Logistic regression analysis demonstrated that treatment recommendations were significantly less likely to be concordant in patients with ATA intermediate‐risk and stage III disease compared with those with ATA low‐risk and stage I disease (odds ratio, 0.16 [ P < .001] and OR, 0.35 [ P = .004], respectively). Conclusions: The authors believe the concordance rate between postsurgical RAI therapy recommendations rendered by WFO and those rendered by physicians was too low to justify adopting WFO for the comprehensive screening of patients with DTC. This is particularly true among patients with ATA intermediate‐risk and stage III disease, reflecting differences in practice patterns between the United States (where WFO was calibrated) and Korea. Hence, WFO is not a substitute for physicians, and also may require regional customization to improve its assistive capability.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2018M3A9E8066253)
This publication has 12 references indexed in Scilit:
- Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor boardAnnals of Oncology, 2018
- Thyroid nodules and cancer management guidelines: comparisons and controversiesEndocrine-Related Cancer, 2017
- A new era of oncology through artificial intelligenceESMO Open, 2017
- AJCC Cancer Staging Manual2017
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2015
- Radioiodine for Thyroid Cancer — Is Less More?New England Journal of Medicine, 2012
- AJCC Cancer Staging Manual2010
- Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotopeJournal of Surgical Oncology, 2007
- Cognitive errors in diagnosis: Instantiation, classification, and consequencesThe American Journal of Medicine, 1989